Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Audio on Switching to Long-Acting ART

Source: Key Decisions in HIV Care
Listen as Daniel R. Kuritzkes, MD, explains key clinical trial data and gives practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure.
Daniel R. Kuritzkes, MD
Released: July 7, 2021

In this episode, Daniel J. Kuritzkes, MD, reviews key clinical trial data and gives practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure. The overview will include analyses of:

  • ATLAS and FLAIR studies of long-acting injectable CAB + RPV
  • ATLAS 2M dosing study
  • FDA approval and DHHS statement on use of long-acting injectable ART
  • Studies on whether an oral lead-in is needed

Presenter:

Daniel R. Kuritzkes, MD
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Follow along with the slides at:
https://bit.ly/3hNfHII

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Clinical Care Options’ (CCO) commentary on patient education for people living with HIV during the COVID-19 pandemic

Sharon L. Walmsley, MSc, MD, FRCPC Released: September 22, 2021

From Dr. Eric Daar and CCO, slides covering new data from IAS 2021 expanding our understanding of the adverse event profiles of specific ART regimens

Eric S. Daar, MD Released: September 22, 2021

From Dr. Eric S. Daar and Clinical Care Options (CCO), expert discussion on how new data from IAS 2021 expand our understanding of adverse events with specific ART regimens

Eric S. Daar, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: September 22, 2021 Expired: September 21, 2022

Clinical Care Options (CCO): patient perspective on the decision to switch to long-acting injectable ART and the impact it has had on her life.

person default Anonymous Patient Released: September 16, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue